#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3430109	Binding	Inhibition of 6-His-tagged human recombinant PDE5A3 expressed in Sf9 cells by scintillation proximity assay	Homo sapiens	1	ALA3425427	cell-based format	Scientific Literature
2.	ALA3602936	Binding	Inhibition of human PDE5A1	Homo sapiens	1	ALA3600381	single protein format	Scientific Literature
3.	ALA3631028	Binding	Inhibition of human PDE5A using AM-Cyclic-3',5'-AMP at 10 uM after 60 mins by fluorescence polarization assay	Homo sapiens	1	ALA3627623	single protein format	Scientific Literature
4.	ALA3631048	Binding	Inhibition of human PDE5A using AM-Cyclic-3',5'-AMP after 60 mins by fluorescence polarization assay	Homo sapiens	1	ALA3627623	single protein format	Scientific Literature
5.	ALA3635532	Binding	Inhibition of recombinant human PDE5A using [3H]cGMP/cGMP as substrate assessed as hydrolysis of [3H]cGMP to [3H]GMP at 1 uM after 30 mins by scintillation proximity assay	Homo sapiens	9	ALA3632475	single protein format	Scientific Literature
6.	ALA3635534	Binding	Inhibition of recombinant human PDE5A using [3H]cGMP/cGMP as substrate assessed as hydrolysis of [3H]cGMP to [3H]GMP at 10 uM after 30 mins by scintillation proximity assay	Homo sapiens	9	ALA3632475	single protein format	Scientific Literature
7.	ALA3706035	Binding	Inhibition Assay: To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1:3) from 200 uM to 0.091 uM are prepared (resulting final concentrations in the test: 4 uM to 0.0018 uM). In each case 2 ul of the diluted substance solutions are placed into the wells of microtitre plates (Isoplate-96/200 W; Perkin Elmer). Subsequently, 50 ul of a dilution of the above-described PDE 5 preparation are added. The dilution of the PDE 5 preparation is selected such that, during the later incubation, less than 70% of the substrate is converted (typical dilution: 1:100; dilution buffer: 50 mM tris/hydrochloric acid pH 7.5, 8.3 mM magnesium chloride, 1.7 mM EDTA, 0.2% BSA). The substrate, [8-3H]cyclic guanosine-3',5'-monophosphate (1 uCi/ul; Perkin Elmer) is diluted 1:2000 with assay buffer (50 mM tris/hydrochloric acid pH 7.5, 8.3 mM magnesium chloride, 1.7 mM EDTA).	Homo sapiens	22	ALA3639285	single protein format	BindingDB Database
8.	ALA3706232	Binding	Caliper Mobility-Shift Assay: A sample to be tested is precisely weighed, dissolved by adding DMSO, mixed sufficiently to form 10 mM solution. The above mother solution is diluted with DMSO to 0.5 mM, then diluted in 3.162 gradient multiple to obtain total 11 concentrations.20 ul of substrate 10 uM FL-cGMP was added to 96-well plate, to which was added 1 ul of compound DMSO solution or compound-free DMSO solution, then was added 29 ul of 1.38 ng/ul PDE-5A enzyme buffer solution (100 mM Hepes pH 7.5, 5 mM MgCl2, 0.002% Brij-35). The maximum final concentration of the compound was 10 uM. After incubation at 30 C. for 1 h, 20 ul of 70 uM EDTA was added to terminate reaction. Substrate and products were separated and analyzed by electrophoresis.	Homo sapiens	18	ALA3638415	single protein format	BindingDB Database
9.	ALA3706016	Binding	Inhibition Assay: By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhibition was calculated and IC50 value against PDE5 was determined. To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GBq/mmol) at a concentration of 33.3 nmol/L, 50 uL of a solution of the compound to be evaluated (formed by dissolving the compound in DMSO and diluting it with distilled water to DMSO concentration of 5%) and 50 uL of the PDE9 protein solution as prepared in the above, as diluted with buffer C (40 mmol/L Tris-HCl, pH7.5, 15 mmol/L benzamidine, 15 mmol/L 2-mercaptoethanol, 1 ug/mL Pepstatin A, 1 ug/mL Leupeptin) by 1,500x, were added under cooling with ice. This mixed solution was incubated at 30 C. for 30 minutes and the enzymatic reaction of PDE9 was terminated by heating the system in boiling water.	Homo sapiens	11	ALA3639000	single protein format	BindingDB Database
10.	ALA3707709	Binding	In Vitro Inhibition Assay: The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. 2 uL portions of the diluted substance solutions are introduced into the wells of microtiter plates (Isoplate; Wallac Inc., Atlanta, Ga.). Then 50 uL of a dilution of the PDE9A preparation described above are added. The dilution of the PDE9A preparation is chosen so that less than 70% of the substrate is converted during the subsequent incubation (typical dilution: 1:10000; dilution buffer: 50 mM Tris/HCl pH 7.5, 8.3 mM MgCl2, 1.7 mM EDTA, 0.2% BSA). The substrate, [8-3H] guanosine 3',5'-cyclic phosphate (1 uCi/uL; Amersham Pharmacia Biotech., Piscataway, N.J.) is diluted 1:2000 with assay buffer (50 mM Tris/HCl pH 7.5, 8.3 mM MgCl2, 1.7 mM EDTA) to a concentration of 0.0005 uCi/uL.	Homo sapiens	1	ALA3639087	single protein format	BindingDB Database
11.	ALA3707823	Binding	Inhibition Assay: The test substances are dissolved in 100% DMSO and serially diluted to determine their in vitro effect on PDE 9A. Typically, serial dilutions from 200 uM to 1.6 uM are prepared (resulting final concentrations in the assay: 4 uM to 0.032 uM). 2 uL portions of the diluted substance solutions are introduced into the wells of microtiter plates (Isoplate; Wallac Inc., Atlanta, Ga.). Then 50 uL of a dilution of the PDE9A preparation described above are added. The dilution of the PDE9A preparation is chosen so that less than 70% of the substrate is converted during the subsequent incubation (typical dilution: 1:10000; dilution buffer: 50 mM Tris/HCl pH 7.5, 8.3 mM MgCl2, 1.7 mM EDTA, 0.2% BSA). The substrate, [8-3H] guanosine 3',5'-cyclic phosphate (1 uCi/uL; Amersham Pharmacia Biotech., Piscataway, N.J.) is diluted 1:2000 with assay buffer (50 mM Tris/HCl pH 7.5, 8.3 mM MgCl2, 1.7 mM EDTA) to a concentration of 0.0005 uCi/uL.	Homo sapiens	1	ALA3638938	single protein format	BindingDB Database
12.	ALA3742950	Binding	Inhibition of human PDE5A using [3H]cAMP as substrate after 30 mins by scintillation proximity assay	Homo sapiens	9	ALA3739392	single protein format	Scientific Literature
13.	ALA3769082	Binding	Inhibition of full length human recombinant PDE5A1 using [3H]-cGMP as substrate by scintillation proximity assay	Homo sapiens	1	ALA3763060	single protein format	Scientific Literature
14.	ALA3772478	Binding	Inhibition of recombinant full lenght human PDE5A using fluorescent labeled cGMP as substrate after 15 mins by IMAP assay	Homo sapiens	5	ALA3769405	single protein format	Scientific Literature
15.	ALA3772729	Binding	Inhibition of PDE5 (unknown origin)	Homo sapiens	7	ALA3769307	single protein format	Scientific Literature
16.	ALA3773479	Binding	Inhibition of PDE5A1 (unknown origin)	Homo sapiens	1	ALA3769388	single protein format	Scientific Literature
17.	ALA3777213	Binding	Binding affinity to human PDE5 at 10 uM	Homo sapiens	1	ALA3774360	single protein format	Scientific Literature
18.	ALA3795221	Binding	Inhibition of PDE5A1 catalytic domain (535 to 860 residues) (unknown origin) using [3H]-cGMP as substrate after 15 mins by liquid scintillation counting method	Homo sapiens	1	ALA3792327	single protein format	Scientific Literature
19.	ALA3810971	Binding	Inhibition of PDE5 (unknown origin) at 10 uM	Homo sapiens	1	ALA3808387	single protein format	Scientific Literature
20.	ALA3815672	Binding	Inhibition of human PDE5A1	Homo sapiens	1	ALA3813640	single protein format	Scientific Literature